Literature DB >> 2536441

1-(2,3-Dideoxy-beta-D-glycero-pent-2-enofuranosyl)thymine. A highly potent and selective anti-HIV agent.

M M Mansuri1, J E Starrett, I Ghazzouli, M J Hitchcock, R Z Sterzycki, V Brankovan, T S Lin, E M August, W H Prusoff, J P Sommadossi.   

Abstract

The nucleoside analogue 1-(2,3-dideoxy-beta-D-glycero-pent-2-enofuranosyl)thymine (d4T, 1) was prepared by ring opening of the 3',5'-anhydro compound 5. This method has been refined such that it can be used to prepare d4T on a large scale. The triphosphate of d4T was also synthesized from 1 in order to examine the mode of action. The in vitro inhibitory activity of d4T was found to be comparable to that of AZT in HIV-infected CEM cells. The triphosphate of d4T (8) and that of AZT inhibited the HIV reverse transcriptase with poly(rA):oligo(dT) as the template:primer with Ki values of 0.032 and 0.007 microM, respectively. The in vitro toxicity of d4T against normal human hematopoietic progenitor cells (CFU-GM) was measured in comparison to AZT. While d4T reduces colony-forming units by 50% at a concentration of 100 microM, it takes only 1 microM AZT to have a similar toxic effect. With erythrocyte burst forming units (BFU-E) the in vitro toxicities for d4T and AZT have comparable ID50 values of 10 and 6.7 microM, respectively.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2536441     DOI: 10.1021/jm00122a029

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  17 in total

Review 1.  Structural modifications of nucleosides in ionic liquids.

Authors:  Vineet Kumar; Virinder S Parmar; Sanjay V Malhotra
Journal:  Biochimie       Date:  2010-02-21       Impact factor: 4.079

2.  Pharmacokinetics of 3'-fluoro-3'-deoxythymidine and 3'-deoxy-2',3'-didehydrothymidine in rats.

Authors:  F D Boudinot; S G Smith; E D Funderburg; R F Schinazi
Journal:  Antimicrob Agents Chemother       Date:  1991-04       Impact factor: 5.191

Review 3.  Antiviral therapy: current concepts and practices.

Authors:  B Bean
Journal:  Clin Microbiol Rev       Date:  1992-04       Impact factor: 26.132

4.  Radioimmunoassay for quantitation of 2',3'-didehydro-3'-deoxythymidine (D4T) in human plasma.

Authors:  X J Zhou; H Chakboub; B Ferrua; J Moravek; R Guedj; J P Sommadossi
Journal:  Antimicrob Agents Chemother       Date:  1996-06       Impact factor: 5.191

5.  Effects of drugs on 2',3'-dideoxy-2',3'-didehydrothymidine phosphorylation in vitro.

Authors:  P G Hoggard; S Kewn; M G Barry; S H Khoo; D J Back
Journal:  Antimicrob Agents Chemother       Date:  1997-06       Impact factor: 5.191

6.  Mutants of feline immunodeficiency virus resistant to 2',3'-dideoxy-2',3'-didehydrothymidine.

Authors:  Y Q Zhu; K M Remington; T W North
Journal:  Antimicrob Agents Chemother       Date:  1996-09       Impact factor: 5.191

7.  In vitro and in vivo disposition and metabolism of 3'-deoxy-2',3'-didehydrothymidine.

Authors:  E M Cretton; Z Zhou; L B Kidd; H M McClure; S Kaul; M J Hitchcock; J P Sommadossi
Journal:  Antimicrob Agents Chemother       Date:  1993-09       Impact factor: 5.191

Review 8.  Pathogenesis, clinical course, and recent issues in HIV-1-infected Japanese hemophiliacs: a three-decade follow-up.

Authors:  Shinichi Oka; Kazuko Ikeda; Misao Takano; Miwa Ogane; Junko Tanuma; Kunihisa Tsukada; Hiroyuki Gatanaga
Journal:  Glob Health Med       Date:  2020-02-29

Review 9.  Antiviral therapy in human immunodeficiency virus infections. Current status (Part II).

Authors:  E Sandström; B Oberg
Journal:  Drugs       Date:  1993-05       Impact factor: 9.546

Review 10.  Metabolism and mechanism of antiretroviral action of purine and pyrimidine derivatives.

Authors:  J Balzarini
Journal:  Pharm World Sci       Date:  1994-04-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.